{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:43:52Z","timestamp":1792511032545,"version":"4.5.0"},"reference-count":37,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP1-RA) have potent glucose-lowering and weight loss benefits, but their effects on bone remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate changes in bone mineral density (BMD) in patients using semaglutide (SEM) and tirzepatide (TIR), a dual agonist of GLP-1\/glucose dependent insulinotropic polypeptide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-center retrospective study. Adult patients using SEM\/TIR for \u22656 months with DXA scans before initiation and at least 6 months after were matched by age, sex, BMI, and diabetes mellitus (DM) to nonusers with at least 2 DXA scans over the same period. The primary outcome was the percentage change in total hip (TH) BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 255 patients using SEM or TIR in the GLP-1 RA group (92% female, mean age 64 \u00b1 9 years, BMI 31.0 \u00b1 5.6 kg\/m\u00b2) and 255 controls. After a median follow-up of 17 months, the GLP-1 RA group achieved a median 5% weight loss. Both groups had significant declines in BMD at TH and FN, with a similar magnitude between groups. In the GLP-1RA group, weight loss was directly associated with bone loss at the TH and FN (r = 0.32 for TH, r = 0.17 for FN, both P &amp;lt; .01). Among patients without DM, greater TH bone loss was noted in the GLP-1 RA group compared to controls (\u22121% vs \u22120.6%, P = .04), whereas TH bone loss was similar between groups among patients with DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SEM\/TIR use was associated with greater annualized TH bone loss in patients without DM, whereas TH bone loss was comparable between GLP-1 RA and controls in patients with DM. These findings suggest GLP-1 RA's effects on bone may differ by DM status, with weight loss driving bone loss in patients without DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag052","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T12:52:39Z","timestamp":1770382359000},"page":"1959-1966","source":"Crossref","is-referenced-by-count":22,"title":["Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5448-3626","authenticated-orcid":false,"given":"Yi","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Walzer","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana P","family":"Shukla","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Chirko","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilissa","family":"Pipia","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Sathi","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uthman","family":"Shukairy","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta R","family":"Kashyap","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, New York Presbyterian Hospital, Weill Cornell Medical College , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M","family":"Stein","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Hospital for Special Surgery , New York, NY 10021 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,8]]},"reference":[{"issue":"1","key":"2026061619570733900_dgag052-B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","journal-title":"N Engl J Med"},{"issue":"10431","key":"2026061619570733900_dgag052-B2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"issue":"25","key":"2026061619570733900_dgag052-B3","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. State-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2026061619570733900_dgag052-B4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2026061619570733900_dgag052-B5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"2026061619570733900_dgag052-B6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3803\/EnM.2023.1673","article-title":"New insights into calorie restriction induced bone loss","volume":"38","author":"Liu","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"2","key":"2026061619570733900_dgag052-B7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S2213-8587(13)70183-9","article-title":"Bone loss after bariatric surgery: causes, consequences, and management","volume":"2","author":"Stein","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2026061619570733900_dgag052-B8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11914-020-00579-2","article-title":"The skeletal consequences of bariatric surgery","volume":"18","author":"Krez","year":"2020","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2026061619570733900_dgag052-B9","doi-asserted-by":"crossref","first-page":"3361309","DOI":"10.1155\/2021\/3361309","article-title":"Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study","volume":"2021","author":"Cai","year":"2021","journal-title":"Biomed Res Int"},{"issue":"8","key":"2026061619570733900_dgag052-B10","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2015-1176","article-title":"GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women","volume":"100","author":"Iepsen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026061619570733900_dgag052-B11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026061619570733900_dgag052-B12","doi-asserted-by":"crossref","first-page":"102624","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"4","key":"2026061619570733900_dgag052-B13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026061619570733900_dgag052-B14","doi-asserted-by":"crossref","first-page":"103212","DOI":"10.1016\/j.dsx.2025.103212","article-title":"Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: a systematic review of phase 3 clinical trials","volume":"19","author":"Singh","year":"2025","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"2026061619570733900_dgag052-B15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00592-017-0973-2","article-title":"Bone health in subjects with type 1 diabetes for more than 50 years","volume":"54","author":"Maddaloni","year":"2017","journal-title":"Acta Diabetol"},{"issue":"4","key":"2026061619570733900_dgag052-B16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/jbmr.4509","article-title":"Distributions of microdamage are altered between trabecular rods and plates in cancellous bone from men with type 2 diabetes mellitus","volume":"37","author":"Sacher","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026061619570733900_dgag052-B17","doi-asserted-by":"crossref","first-page":"e2433326","DOI":"10.1001\/jamanetworkopen.2024.33326","article-title":"One-year weight reduction with semaglutide or liraglutide in clinical practice","volume":"7","author":"Gasoyan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2026061619570733900_dgag052-B18","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"2026061619570733900_dgag052-B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"2026061619570733900_dgag052-B20","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"2026061619570733900_dgag052-B21","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10402","key":"2026061619570733900_dgag052-B22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"2026061619570733900_dgag052-B23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-024-03896-z","article-title":"Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: an updated systematic review and meta-analysis including the latest SURMOUNT-2 trial","volume":"86","author":"Qin","year":"2024","journal-title":"Endocrine"},{"issue":"7","key":"2026061619570733900_dgag052-B24","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"2026061619570733900_dgag052-B25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"2026061619570733900_dgag052-B26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s13300-025-01711-0","article-title":"Tirzepatide for older adults with type 2 diabetes and without obesity: a post hoc analysis of the SURPASS clinical trials","volume":"16","author":"Rasouli","year":"2025","journal-title":"Diabetes Ther"},{"issue":"6","key":"2026061619570733900_dgag052-B27","doi-asserted-by":"crossref","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"12","key":"2026061619570733900_dgag052-B28","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/jbmr.2564","article-title":"Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials","volume":"30","author":"Zibellini","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026061619570733900_dgag052-B29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11695-020-05095-x","article-title":"Changes in bone mineral density after weight loss due to metabolic surgery or lifestyle intervention in obese patients","volume":"31","author":"Chen","year":"2021","journal-title":"Obes Surg"},{"issue":"12","key":"2026061619570733900_dgag052-B30","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/jbmr.3555","article-title":"Effect of exercise modality during weight loss on bone health in older adults with obesity and cardiovascular disease or metabolic syndrome: a randomized controlled trial","volume":"33","author":"Beavers","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2026061619570733900_dgag052-B31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1210\/jc.2012-2394","article-title":"Bariatric surgery results in cortical bone loss","volume":"98","author":"Stein","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026061619570733900_dgag052-B32","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00592-015-0792-2","article-title":"Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes","volume":"52","author":"Li","year":"2015","journal-title":"Acta Diabetol"},{"key":"2026061619570733900_dgag052-B33","doi-asserted-by":"crossref","first-page":"115197","DOI":"10.1016\/j.bone.2019.115197","article-title":"Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial","volume":"132","author":"Hygum","year":"2020","journal-title":"Bone"},{"issue":"2","key":"2026061619570733900_dgag052-B34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00223-024-01240-1","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic osteopathy: another positive effect of incretines? A 12 months longitudinal study","volume":"115","author":"Al Refaie","year":"2024","journal-title":"Calcif Tissue Int"},{"key":"2026061619570733900_dgag052-B35","doi-asserted-by":"crossref","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-kappaB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2026061619570733900_dgag052-B36","doi-asserted-by":"crossref","first-page":"1539411","DOI":"10.3389\/fphar.2025.1539411","article-title":"Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the wnt\/LRP5\/beta-catenin signaling pathway","volume":"16","author":"Tian","year":"2025","journal-title":"Front Pharmacol"},{"issue":"12","key":"2026061619570733900_dgag052-B37","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/ph17121655","article-title":"Effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice","volume":"17","author":"Lv","year":"2024","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag052\/66804108\/dgag052.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1959\/66804108\/dgag052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/7\/1959\/66804108\/dgag052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:57:21Z","timestamp":1781654241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/7\/1959\/8467122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,8]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,8]]},"published-print":{"date-parts":[[2026,6,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag052","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,8]]}}}